Press Releases

2014

August 13, 2014
Spectral Announces Second Quarter, 2014 Results


July 25, 2014
Spectral Diagnostics and Toray Industries Announce Closing of Tranche "A" Component of Its Up to $18.2 Million Offering


July 22, 2014
Spectral Diagnostics Announces Shareholder Approval of Its Up to $18.2 Million Offering


July 8, 2014
Spectral Announces ISS and Glass Lewis Recommendations to Vote in Favour of Its Up To $18.2 Million Offering


June 11, 2014
Spectral Diagnostics Announces Proposed Offering of up to $18.2 Million


June 3, 2014
U.S. FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial


May 15, 2014
Spectral Announces First Quarter, 2014 Results


May 6, 2014
Spectral Diagnostics Provides Update on Results of Annual and Special Meeting of Shareholders


April 21, 2014
Spectral Diagnostics Announces Leading Independent Proxy Firms Recommend Spectral Shareholders Vote For Name Change and For Amendment of Warrants


April 14, 2014
Spectral Updates Status of EUPHRATES Trial


March 27, 2014
Spectral Announces Fourth Quarter and Fiscal 2013 Results


March 11, 2014
Spectral Diagnostics Provides Clinical Update on the EUPHRATES Trial


February 24, 2014
Spectral Diagnostics Announces Extension of Warrants


January 28, 2014
Spectral Announces Status of Second Interim Analysis


2013

November 13, 2013
Spectral Announces Third Quarter 2013 Results


September 26, 2013
Spectral Reaches Enrollment Milestone for its Phase III EUPHRATES Trial


August 13, 2013
Spectral Announces Second Quarter 2013 Results


August 1, 2013
Spectral to Present at Wedbush Life Sciences Conference

Spectral's Presentation at Wedbush Life Sciences Conference, August 14, 2013

If you have any problems accessing the file, try right clicking your mouse and 'Save As' or 'Open in new window' or check your browser settings.


July 31, 2013
Spectral Provides Update on its EUPHRATES Trial


July 26, 2013
Spectral Diagnostics Announces Board Changes


May 24, 2013
Spectral Diagnostics Annual General Meeting of Shareholders Presentation

If you have any problems accessing the file, try right clicking your mouse and 'Save As' or 'Open in new window' or check your browser settings.


May 23, 2013
Spectral Diagnostics Provides Update on Results of Annual and Special Meeting


May 15, 2013
Spectral Announces First Quarter 2013 Results


May 7, 2013
Spectral Appoints Vice President of Sales and Marketing


April 16, 2013
Spectral Diagnostics Adopts New By-Laws Which Contain Advance Notice Provisions


April 2, 2013
Spectral Diagnostics Closes $5.6 Million Offering


March 27, 2013
Spectral Announces Fourth Quarter and Fiscal 2012 Results


March 18, 2013
Spectral Diagnostics Increases Offering to $5.6 Million


March 7, 2013
Toray Industries Makes $5 Million Strategic Investment in Spectral Diagnostics


February 4, 2013
Spectral Announces Results of First Interim Analysis by Data Safety and Monitoring Board


2012

December 5, 2012
Spectral Announces Enrollment Milestone for its Euphrates Trial


November 14, 2012
Spectral Announces Third Quarter 2012 Results


November 9, 2012
Spectral Announces New Clinical Data is Being Presented at International Sepsis Forum


November 1, 2012
Spectral Diagnostics Investor Presentation, Fall 2012


September 26, 2012
FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial


September 4, 2012
Spectral to Present at Rodman & Renshaw Annual Global Investment Conference on September 10 - Company will also attend World Sepsis Day in New York on September 13

Spectral’s Presentation at Rodman & Renshaw 14th Annual Healthcare Conference

If you have any problems accessing the file, try right clicking your mouse and 'Save As' or 'Open in new window' or check your browser settings.


August 16, 2012
Spectral and Toray Expand EAA™/PMX Theranostic to Saudi Arabia and Turkey


August 14, 2012
Spectral Announces Second Quarter 2012 Results


June 25, 2012
Spectral Diagnostics Annual General Meeting of Shareholders Presentation

If you have any problems accessing the file, try right clicking your mouse and 'Save As' or 'Open in new window' or check your browser settings.


June 20, 2012
Spectral Diagnostics Provides Update on Euphrates Trial


June 12, 2012
Spectral Diagnostics to Present at Bloom Burton & Co. Healthcare Investor Conference


May 17, 2012
Spectral Diagnostics to Present at BioFinance 2012


May 15, 2012
Spectral Announces First Quarter 2012 Results


March 16, 2012
Spectral Announces Fourth Quarter and 2011 Results


January 11, 2012
Spectral Begins Trading on OTCQX


January 4, 2012
Spectral Diagnostics Provides Corporate Update


2011

December 5, 2011
Op-Ed by Spectral Diagnostics CEO in The Globe and Mail


November 11, 2011
Spectral Diagnostics Inc. Announces Normal Course Issuer Bid


November 10, 2011
Spectral Announces Third Quarter Results


October 25, 2011
Spectral to Expand its Phase III Sepsis Trial to Canadian Sites


September 28, 2011
Spectral's Endotoxin Activity Assay Featured in Major Publication


September 9, 2011
Medwell Capital and Spectral Diagnostics Announce Completion of Plan of Arrangement


September 6, 2011
Spectral to Present at Rodman & Renshaw Annual Global Investment Conference on September 13


August 29, 2011
Medwell Capital and Spectral Diagnostics announce court approval of Plan Of Arrangement and set closing and record date for completion


August 26, 2011
Spectral Shareholders Approve Previously Announced $10 Million Private Placement


August 16, 2011
Spectral Diagnostics Announces Leading Independent Proxy Firms Recommend Spectral Shareholders Vote for the Proposed Private Placement of Spectral Shares to Medwell Capital Corp.


August 11, 2011
Spectral Announces Second Quarter Results


August 3, 2011
Spectral Diagnostics Issues Corporate Update


August 2, 2011
Video: Spectral Diagnostics CEO Paul Walker talks about the market opportunity for the Company’s theranostics product for the treatment for severe sepsis


June 28, 2011
Medwell Capital and Spectral Diagnostics Announce Plan of Arrangement


May 19, 2011
Spectral Diagnostics to Present at BioFinance 2011


May 12, 2011
Spectral Announces First Quarter Results


May 5, 2011
Spectral Achieves Important Milestone in its Pivotal U.S. Clinical Trial for Sepsis


April 11, 2011
Spectral Diagnostics Refiles Third Quarter Unaudited Interim Financial Statements


March 28, 2011
Medwell Capital and a Consortium of Buyers Acquire Spectral Diagnostic Shares from GrowthWorks Canadian Fund


March 10, 2011
Spectral Diagnostics Announces Fourth Quarter and 2010 Year End Results

 

2010

December 31, 2010
Spectral Diagnostics Completes Conversion of Promissory Notes


November 22, 2010
Spectral Obtains Exclusive Canadian Distribution Rights for Toraymyxin™


November 15, 2010
Spectral Announces Third Quarter 2010 Results


October 19, 2010
Spectral Initiates U.S. Pivotal Trial of Toraymyxin™ in Septic Shock


September 13, 2010
Spectral to Present at Rodman & Renshaw Annual Global Investment Conference on September 13

Spectral's Rodman & Renshaw Presentation 

If you have any problems accessing the file, try right clicking your mouse and 'Save As' or 'Open in new window' or check your browser settings.


August 12, 2010
Spectral Announces Second Quarter 2010 Results


June 23, 2010
Spectral Receives McMaster Industry Partner of the Year Award for Aptamer Discovery Research


May 14, 2010
Spectral Announces First Quarter Financial Results


March 12, 2010
Spectral Announces Presentations at the 8th Annual World Congress on Trauma, Shock, Inflammation and Sepsis Focusing on the Role of Endotoxin


March 11, 2010
Spectral Announces 2009 Results


March 10, 2010
Spectral Appoints Two New Board Members


March 3, 2010
Spectral Closes $19.5 Million Private Placement Financing


March 2, 2010
Spectral Granted IDE Approval by U.S. FDA to Conduct Pivotal Trial for Toraymyxin™


February 26, 2010
Spectral Shareholders Approve $19.5 Million Private Placement Financing


February 3, 2010
Spectral Increases Private Placement Financing to $19.5 Million


2009

December 17, 2009
Spectral Diagnostics Raises $14 Million and Enters into Strategic Collaboration with BIOMS Medical to Commercialize Treatment for Sepsis


Spectral & BioMS Audiocast View a slide presentation and audio recording by Dr. Paul Walker, President and CEO of Spectral and Mr. Kevin Giese, President and CEO of BioMS Medical where they discuss this collaboration and the opportunity for Toraymyxin™ in the treatment of severe sepsis.


November 12, 2009
Spectral Announces Third Quarter 2009 Results


August 13, 2009
Spectral Appoints New Board Member


August 13, 2009
Spectral Announces Second Quarter 2009 Results


June 18, 2009
Spectral Announces Publication Demonstrating Toraymyxin™ Significantly Reduces Mortality from Sepsis in Prospective Controlled Trial


May 14, 2009
Spectral Announces First Quarter 2009 Results


March 25, 2009
Spectral Announces Presentations at the 29th International Symposium on Intensive Care and Emergency Medicine Focusing on the Role of Endotoxin

© 2011 Spectral Diagnostics Inc.